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Becker muscular dystrophy (BMD) and Duchenne muscular
dystrophy (DMD) are X-linked genetic disorders involving
abnormal dystrophin synthesis.1 Cardiac involvement is
frequent in these disorders. Echocardiograms show abnormal
systolic function of the left ventricle (LV) in 50%–70% of
BMD patients, whereas evidence of myocardial damage
detected by cardiac magnetic resonance (CMR) imaging can
be found even in patients with normal echocardiograms.2–4
Some mutations in the dystrophin gene cause isolated
cardiomyopathy without skeletal myopathy.5 Although ven-
tricular arrhythmias appear to be a common manifestation of
dystrophin-associated cardiomyopathy, their mechanism and
arrhythmogenic substrate are poorly characterized.2
We report a case of recurrent drug-refractory ventricular
tachycardia (VT) treated with epicardial ablation in a BMD
patient with dilated cardiomyopathy.Case report
The patient is a 26-year-old male with a history of BMD due
to deletion of exons 38–43 in the dystrophin gene. The
disease was ﬁrst diagnosed in 2005 when he presented to a
pediatric neurology clinic with proximal muscle weakness
and elevated creatinine kinase levels. A multigated acquis-
ition scan, done as a part of his initial workup, revealed an
LV ejection fraction (LVEF) of 36%. In 2011, in view of
progressive worsening of his LV systolic function despite
optimal medical therapy (LVEF of 20% by echocardiogram),
he underwent placement of a primary prevention implantable
cardioverter deﬁbrillator (ICD). In June 2013, he received an
ICD shock for syncopal monomorphic VT at a rate of 260
beats per minute (bpm). ICD interrogation also showed
multiple logged nonsustained VTs. He was subsequently
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).relative quiescence, the patient presented to an outside hos-
pital with recurrent VT requiring 2 ICD shocks. The mainte-
nance dosage of amiodarone was temporarily increased from
200 to 400 mg a day. In April 2015, he presented with
another episode of syncope. ICD interrogation revealed 2
additional episodes of monomorphic VT (230–250 bpm)
terminated by shocks. VT ablation was thus pursued. A
preprocedure contrast-enhanced cardiac computed tomogra-
phy (CT) image showed severely enlarged LV (LV-end
diastolic volume and end systolic volume of 366 mL and 256
mL, respectively), LVEF of 30%, global hypokinesis, and
akinesis of the inferolateral wall of the LV. The right
ventricle was normal. First-pass contrast-enhanced images
suggested loss of myocardium predominantly within the
inferolateral wall of the LV (Figure 1A). Delayed enhance-
ment was noted in these segments, with sparing of the
subendocardium. An epicardial origin of his arrhythmia was
suspected based on the latter ﬁnding as well as previously
published postmortem and CMR series showing predom-
inantly subepicardial involvement in dystrophin-associated
cardiomyopathies (please see the Discussion section).
The patient presented to the electrophysiology (EP)
laboratory in sinus rhythm (SR) with intermittent atrial
pacing at a rate of 65 bpm. Surface electrocardiogram
(ECG) showed a right bundle branch block (RBBB) intrinsic
QRS pattern with QRS duration of 190 milliseconds and PR
interval of 250 milliseconds. The AH interval was 75
milliseconds and HV interval was 84 milliseconds. An
intracardiac ultrasound probe (CARTO Sound, Biosense
Webster, Diamond Bar, CA) and an electroanatomic map-
ping (EAM) system (CARTO 4, Biosense Webster) were
then used to create endocardial geometries of the ventricles.
After obtaining pericardial access, a high-density epicar-
dial voltage map was obtained in SR using a decapolar
catheter (DecaNav, Biosense Webster). The mapping cath-
eter was placed into the pericardium via a steerable sheath
used for better maneuverability and support (40 cm, Agilis,
St Jude Medical, St Paul, MN). There was a large area of
low-amplitude (o1 mV) fractionated electrograms (EGMs)
in the inferolateral wall of the LV consistent with “scar”
(Figure 1B).6 The “scar” area corresponded to the area of
abnormal substrate on the CT images (Figures 1A and 1B).pen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Evidence of myocardial damage on cardiac
magnetic resonance images is found in a majority
of patients with muscular dystrophies involving
abnormal dystrophin synthesis (Becker and
Duchenne muscular dystrophies).
 Subepicardial ﬁbrosis of the inferolateral wall of
the left ventricle (LV) is a pathological hallmark of
dystrophin-associated cardiomyopathies.
Subendocardial myocardium is usually spared.
 In our case, the area of abnormal electroanatomic
substrate was conﬁned entirely to the epicardial
surface of the inferolateral LV, whereas endocardial
LV mapping was normal. This case report highlights
importance of epicardial ventricular tachycardia
(VT) mapping in patients with dystrophin-
associated cardiomyopathies.
 Contrast-enhanced cardiac computed tomography
can be potentially useful for localizing of abnormal
myocardial substrate in patients with an implantable
cardioverter deﬁbrillator undergoing VT ablation.
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noted predominantly at the border of the “scar” (Figure 1C).
Following transseptal access, high-density SR endocardialFigure 1 A: Electrocardiogram-gated cardiac computed tomography image with a v
(LV). Note an area of hypoenhancement in the inferolateral wall of the LV (arrows) sugg
extensive area of low-amplitude (o1mV) and fractionated electrograms consistent with “
induced ventricular tachycardia are shown as blue spheres. Teal and red spheres represent
are marked with white spheres. C: An example of high-frequency multicomponent potvoltage mapping of the LV was performed with a duodec-
apolar catheter (Pentaray, Biosense Webster). This mapping
demonstrated normal voltage (41.5 mV) and EGM mor-
phology over the entire endocardial surface of the LV.
A monomorphic VT with RBBB/superior-axis QRS
morphology and a cycle length (CL) of 305 milliseconds
was easily (double extrastimuli) and reproducibly induced
with programmed ventricular stimulation (Figure 2A). There
were no identiﬁable His potentials. Twelve-lead QRS
morphology of the tachycardia suggested its epicardial origin
(slurring in the initial portion of the QRS, inferior Q waves,
pseudo delta wave of 95 milliseconds, and a maximum
deﬂection index of 0.6 milliseconds).7,8 Detailed activation
and entrainment mapping was not feasible, because of rapid
hemodynamic compromise and inconsistent ventricular cap-
ture at the maximum output over most of the attempted
pacing sites within the epicardial “scar.” Thus, brief epi-
cardial activation mapping with the decapolar catheter during
VT was limited to the area exhibiting high-frequency
potentials in SR. Sites showing sharp high-frequency mid-
or continuous diastolic potentials were tagged on the map
(Figures 1B and 2B). VT CL transiently increased from 305
to 330 milliseconds during mapping at these sites. Endocar-
dial LV mapping during VT was not done. Coronary
angiography of the left coronary system was then performed,
and the angiogram was registered to the epicardial map using
the UNIVU technology (Biosense Webster) to avoid ablating
directly near the coronary arteries. High-output pacing was
performed to mark the course of the phrenic nerve (PN)olumetric, color-coded, ﬁrst-pass contrast enhancement map of the left ventricle
esting abnormal myocardial substrate. B: Epicardial voltage map demonstrates an
scar” in the inferolateral LV. Sites with diastolic potentials recorded during initially
ablation lesions color-coded according to their duration. Phrenic nerve capture sites
entials (Maps 1–5) recorded in the area of epicardial “scar” in sinus rhythm.
Figure 2 A: Twelve-lead electrocardiogram of the initially induced ventricular tachycardia. B: Examples of high-frequency diastolic potentials (Maps 4 and
5) recorded in the area of the epicardial “scar.”
Figure 3 Twelve-lead electrocardiograms of ventricular tachycardias
induced following initial ablation.
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showing diastolic potentials during the tachycardia. Because
the course of the PN was directly over the ablation target
area, a peripheral angioplasty balloon catheter (Armada 35
PTA 14  6 cm, Abbott Vascular, Santa Clara, CA) was
used to mechanically displace the parietal pericardium.9 An
externally irrigated–tip catheter (ThermoCool SmartTouch,
Biosense Webster) was used for ablation. Before each
radiofrequency application, high-output pacing was per-
formed to ensure lack of PN capture. Following ablation at
the tagged sites, the targeted VT was no longer inducible.
Two other VT morphologies, which were suspected to be
epicardial in origin, were then induced with a more aggres-
sive pacing protocol (Figure 3). Additional ablation lesions
were empirically delivered at the sites showing low-
amplitude high-frequency potentials in SR. Because the
patient was marginally stable at the end of the procedure,
further VT induction attempts were deemed unsafe. A few
hours after the procedure, he had 2 episodes of fast VT (320–
330 bpm) thought to be triggered by a pericardial drain left in
the area of the arrhythmogenic “scar.” The drain was
subsequently removed. His previous antiarrhythmic regimen
with amiodarone was resumed. He has had no further VT
recurrences over the ensuing 6 months.
Discussion
To the best of our knowledge, this report is the ﬁrst to
describe arrhythmogenic electroanatomic substrate in a
patient with BMD. The area of abnormal EGMs consistent
with “scar” was conﬁned entirely to the epicardial surface of
the LV. Although detailed mapping was not feasible, QRSmorphology, EP ﬁndings, and response to ablation of the
initially induced VT strongly suggest its origin at the area of
the epicardial “scar.” QRS morphologies of other induced
VTs are also suspicious for their epicardial origin. However,
mapping of these VTs was not done.
EAM ﬁndings in the present case are consistent with the
results of previously published pathology and CMR series in
patients with DMD- and BMD-associated cardiomyopathies.
Postmortem heart studies have shown that early cardiac
involvement in DMD characteristically presents with ﬁbrosis
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lateral LV. In advanced cardiomyopathy, diffuse myocardial
ﬁbrosis of the LV and interventricular septum is usually
seen. However, subendocardial myocardium is typically
spared.10,11 More recently, CMR studies in patients with
DMD and BMD have demonstrated characteristic subepi-
cardial distribution patterns of late gadolinium enhancement
primarily involving the inferolateral LV.3,4 The exact mech-
anism of preferential damage of the subepicardial myocar-
dium in the inferolateral LV wall in patients with dystrophin-
associated cardiomyopathies remains unclear. A potential
explanation is that this region might be exposed to higher
mechanical stress than other regions of the heart and thus is
more susceptible to damage in patients with dystrophin
mutations or other conditions.2,4 Interestingly, a similar
pathological pattern is commonly observed in patients with
viral myocarditis. It has been shown that dystrophin dis-
ruption is a key mechanism of myocardial damage in
enterovirus-induced myocarditis.12
Bundle branch reentry (BBR) is another potential mech-
anism of VT in patients with dystrophin-associated cardio-
myopathies due to common involvement of the
intraventricular conduction system. A case of BBR VT has
been previously reported in a patient with BMD.13 However,
the prevalence of BBR VT in these patients is unknown.
Preablation contrast-enhanced cardiac CT was used to
identify abnormal myocardium prior to ablation. Although
gadolinium-enhanced CMR remains the gold standard for
characterizing myocardial pathology and has been shown to
facilitate the decision about the need for pericardial access in
cardiomyopathy patients undergoing VT ablation,14 it is
generally contraindicated in patients with a non-CMR
compatible ICD system. Contrast-enhanced cardiac CT has
recently emerged as a possible alternative imaging technol-
ogy to CMR in ICD patients.15
This case report highlights the importance of epicardial VT
mapping in patients with dystrophin-associated cardiomyo-
pathies. Contrast-enhanced cardiac CT can be potentiallyuseful for localizing abnormal myocardial substrate in ICD
patients undergoing VT ablation.
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